HIGH-VOLUME DENTAL EVACUATOR SUPPLY BUSINESS PLAN
I. Executive Summary
Company Description
The company is a privately held medical device manufacturer based in Austin, Texas, registered to begin operations in 2026. It operates in the dental technology sector and produces high-volume evacuation (HVE) systems that improve clinical safety and indoor air quality by capturing aerosols at source. One-liner: We make dental suction that protects staff, patients, and air.
We sell directly to dental practices across the U.S., bypassing distributors to lower price and speed delivery. Our products combine proprietary ergonomic designs to cut clinician fatigue with validated high-flow performance. Short-term goals are to complete FDA compliance, start pilot deployments, and reach first commercial revenue in 2026; long-term goals are nationwide adoption, 15–25% penetration of target mid-size practices within five years, and sustained gross margins above 60%. One-liner: Direct sales, better ergonomics, and measurable air quality gains set us apart.
Problem
Dental procedures generate airborne aerosols and splatter that carry pathogens and contaminate operatory air. Standard intraoral suction and low-volume saliva ejectors often fail to capture contaminants at the source, leaving aerosolized particles suspended in rooms and on surfaces.
Consequences for practices include increased infection transmission risk, higher compliance and liability exposure, longer room turnover cleaning time, clinician fatigue during long procedures, and reduced procedural throughput and revenue.
There is a clear gap: existing solutions do not provide specialized, ergonomic high-volume evacuation (HVE) devices that simultaneously improve air quality and reduce clinician fatigue. Addressing this gap is necessary to lower infection risk, shorten room turnover, and restore clinical capacity.
One-liner: Current suction tools under-capture aerosols, creating safety, compliance, and throughput problems that require specialized HVE solutions.
Solution
Dental procedures generate aerosols and splatter that standard suction tools fail to capture, raising infection risk and causing clinician strain. We supply a complete evacuation ecosystem — a primary high-volume suction system, precision disposable tips, and HEPA filter cartridges — engineered from medical-grade polymers with high-efficiency motor assemblies to capture >98% of aerosols, reduce noise and weight, and lower total cost of ownership for independent practices.
One-liner: A complete evacuation ecosystem that captures >98% of aerosols to raise operatory safety, with 1,500 units headed to the U.S. in 2026.
Mission Statement
We revolutionize dental operatory safety by delivering the most advanced, ergonomic, and accessible aerosol capture technology to clinicians. We commit to protecting the health of dental professionals and patients through continuous innovation in high-volume evacuation and direct partnership with practitioners. Our goal is to set a new global standard for infection control in dentistry while improving clinical outcomes and the daily working environment for dental teams.
Key Success Factors
Critical operational, financial, and product benchmarks that must hold to deliver investor returns and market traction.
-
98% aerosol capture rate providing a clear clinical advantage over standard suction tools.
-
Direct-to-practice model enabling high margins and a competitive price of $1,250 per system.
-
February 2026 breakeven milestone to secure long-term financial stability.
-
Maintain 14.98% IRR and 23.7% ROE to preserve investor confidence and access to growth capital.
-
Scale consumable tips to 1,400,000 units by 2030 to establish durable recurring revenue.
Financial Summary
Financial highlights show rapid scale: Year 1 revenue $2,568,000 growing to $11,416,000 by Year 5 with strong early profitability.
Ratio | 2026 | 2027 | 2028 |
Projected Revenue | $2,568,000 | $3,994,000 | $5,974,000 |
Projected EBITDA | $944,000 | $1,476,000 | $4,570,000 |
Expected ROI | 14.98% / 23.7% | 14.98% / 23.7% | 14.98% / 23.7% |
The business requires a minimum cash balance of $1,033,000, expected to be met in Feb-26; breakeven occurs in Feb-26 with a total payback of 13 months and project IRR of 14.98% (ROE 23.7%).
Overall financial outlook: profitable early and scalable to double‑digit returns.
Funding Requirements
We request $1,718,000 to fund confirmed capital expenditures and the launch-phase cash minimum required to reach breakeven in February 2026.
Categories | Amount, USD |
Manufacturing Injection Molds | $120,000 |
Assembly Line Automation Equipment | $250,000 |
E-commerce Platform Development | $45,000 |
Laboratory Testing Equipment | $80,000 |
Warehouse Racking and Forklifts | $65,000 |
Office Technology and Server Setup | $30,000 |
Initial Prototype Tooling | $55,000 |
Facility Security and HVAC Upgrades | $40,000 |
Working capital | $1,033,000 |
Total funding required | $1,718,000 |
Financial summary: Year 1 revenue is forecast at $2,568,000 growing to $11,416,000 by Year 5; EBITDA is $944,000 in 2026 rising to $9,139,000 by 2030; project IRR is 14.98% with a 23.7% return on equity, breakeven in February 2026, and a 13-month total payback; the $1,033,000 minimum cash requirement is expected to be met in Q1 of operations.